Neill R Graff-Radford

List of Publications by Year
in descending order

373 papers	30,416 citations	6592 79 h-index	7496 151 g-index
412 all docs	412 docs citations	412 times ranked	28105 citing authors

#	Article	IF	Citations
1	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
2	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates Aî², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
3	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
4	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurology, The, 2011, 10, 785-796.	4.9	733
5	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	15.2	610
6	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581
7	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	3.8	493
8	Understanding the impact of sex and gender in Alzheimer's disease: A call to action. Alzheimer's and Dementia, 2018, 14, 1171-1183.	0.4	468
9	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
10	Association of Low Plasma Aî²42/Aî²40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease. Archives of Neurology, 2007, 64, 354.	4.9	400
11	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
12	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	4.9	383
13	Non-Stationarity in the â€œResting Brainâ€™sâ€•Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
14	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
15	Human whole genome genotype and transcriptome data for Alzheimerâ€™s and other neurodegenerative diseases. Scientific Data, 2016, 3, 160089.	2.4	361
16	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	15.2	351
17	Longitudinal tau PET in ageing and Alzheimerâ€™s disease. Brain, 2018, 141, 1517-1528.	3.7	309
18	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302

#	Article	IF	Citations
19	Spread of pathological tau proteins through communicating neurons in human Alzheimerâ€™s disease. Nature Communications, 2020, 11, 2612.	5.8	283
20	Methodological consensus on clinical proton MRS of the brain: Review and recommendations. Magnetic Resonance in Medicine, 2019, 82, 527-550.	1.9	280
21	Clinicopathologic and¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimerâ€™s disease spectrum. Brain, 2015, 138, 1370-1381.	3.7	270
22	A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. NeuroImage: Clinical, 2016, 11, 802-812.	1.4	249
23	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	7.1	242
24	Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Medicine, 2011, 12, 445-453.	0.8	236
25	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathologica, 2015, 130, 877-889.	3.9	235
26	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
27	Widespread brain tau and its association with ageing, Braak stage and Alzheimerâ€™s dementia. Brain, 2018, 141, 271-287.	3.7	218
28	Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.4	205
29	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
30	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	4.9	195
31	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	0.5	193
32	TDP-43 represses cryptic exon inclusion in the FTDâ€“ALS gene UNC13A. Nature, 2022, 603, 124-130.	13.7	193
33	Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2007, 28, 1330-1339.	1.5	185
34	Association of type 2 diabetes with brain atrophy and cognitive impairment. Neurology, 2014, 82, 1132-1141.	1.5	180
35	Mayo's Older Americans Normative Studies: Category Fluency Norms. Journal of Clinical and Experimental Neuropsychology, 1998, 20, 194-200.	0.8	179
36	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175

#	Article	IF	Citations
37	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
38	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimerâ€™s disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	5.8	172
39	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
40	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
41	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.4	166
42	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
43	APOE Îµ4/Îµ4 diminishes neurotrophic function of human iPSC-derived astrocytes. Human Molecular Genetics, 2017, 26, 2690-2700.	1.4	162
44	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
45	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
46	Improved DTI registration allows voxel-based analysis that outperforms Tract-Based Spatial Statistics. NeuroImage, 2014, 94, 65-78.	2.1	155
47	AVâ€1451 tau and Î²â€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
48	Alzheimer Disease: Postmortem Neuropathologic Correlates of Antemortem¹H MR Spectroscopy Metabolite Measurements¹. Radiology, 2008, 248, 210-220.	3.6	147
49	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	4.5	144
50	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
51	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142
52	Comparative Diagnostic Utility of Different MR Modalities in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2002, 14, 198-207.	0.7	135
53	TREM2 is associated with increased risk for Alzheimerâ€™s disease in African Americans. Molecular Neurodegeneration, 2015, 10, 19.	4.4	130
54	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129

#	Article	IF	Citations
55	White matter hyperintensities: relationship to amyloid and tau burden. Brain, 2019, 142, 2483-2491.	3.7	126
56	Vascular Imaging Abnormalities and Cognition. Stroke, 2015, 46, 433-440.	1.0	125
57	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
58	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
59	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117
60	Spt4 selectively regulates the expression of C9orf72 sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
61	Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases. Alzheimer's and Dementia, 2018, 14, 352-366.	0.4	116
62	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
63	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
64	1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. Journal of the International Neuropsychological Society, 2002, 8, 934-942.	1.2	109
65	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
66	Association of MAPT haplotypes with Alzheimerâ€™s disease risk and MAPT brain gene expression levels. Alzheimer's Research and Therapy, 2014, 6, 39.	3.0	106
67	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
68	APOE Îµ2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	5.8	100
69	Frontotemporal Dementia. Seminars in Neurology, 2007, 27, 048-057.	0.5	98
70	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
71	The Kronos Early Estrogen Prevention Study (KEEPS). Menopause, 2019, 26, 1071-1084.	0.8	97
72	MRI and MRS predictors of mild cognitive impairment in a population-based sample. Neurology, 2013, 81, 126-133.	1.5	95

#	Article	IF	Citations
73	Two rare AKAP9 variants are associated with Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2014, 10, 609.	0.4	94
74	Early Postmenopausal Transdermal 17Î²-Estradiol Therapy and Amyloid-Î² Deposition. Journal of Alzheimer's Disease, 2016, 53, 547-556.	1.2	94
75	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
76	Preeclampsia and cognitive impairment later in life. American Journal of Obstetrics and Gynecology, 2017, 217, 74.e1-74.e11.	0.7	93
77	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
78	Alzheimer CSF biomarkers may be misleading in normal-pressure hydrocephalus. Neurology, 2014, 83, 1573-1575.	1.5	90
79	Late-onset Alzheimerâ€™s risk variants in memory decline, incident mild cognitive impairment, and Alzheimerâ€™s disease. Neurobiology of Aging, 2015, 36, 60-67.	1.5	90
80	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
81	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
82	Neurological manifestations of autosomal dominant familial Alzheimerâ€™s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	4.9	87
83	Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. Alzheimer's and Dementia, 2017, 13, 119-129.	0.4	87
84	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy, 2018, 14, 1404-1418.	4.3	87
85	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
86	Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology, 2013, 80, 911-918.	1.5	86
87	Population-Based Prevalence of Cerebral Cavernous Malformations in Older Adults. JAMA Neurology, 2017, 74, 801.	4.5	81
88	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. NeuroRx, 2004, 1, 196-205.	6.0	80
89	Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e301.	3.1	78
90	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	1.5	78

#	Article	IF	Citations
91	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
92	Hippocampal Volumes, Proton Magnetic Resonance Spectroscopy Metabolites, and Cerebrovascular Disease in Mild Cognitive Impairment Subtypes. Archives of Neurology, 2008, 65, 1621-8.	4.9	75
93	Neuropathologic differences by race from the National Alzheimer's Coordinating Center. Alzheimer's and Dementia, 2016, 12, 669-677.	0.4	75
94	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	4.4	75
95	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74
96	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
97	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
98	Validation of a Serum Screen for Alzheimer's Disease Across Assay Platforms, Species, and Tissues. Journal of Alzheimer's Disease, 2014, 42, 1325-1335.	1.2	73
99	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.4	72
100	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	3.7	70
101	Ante mortem amyloid imaging and Î²-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
102	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
103	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
104	Sex and age interact to determine clinicopathologic differences in Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 873-885.	3.9	69
105	Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurology, 2019, 76, 95.	4.5	69
106	Prosaposin is a regulator of progranulin levels and oligomerization. Nature Communications, 2016, 7, 11992.	5.8	68
107	Amyloid-Î² deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
108	Entorhinal cortex tau, amyloid-Î², cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68

#	Article	IF	Citations
109	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	3.7	66
110	Î²-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
111	Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neurology: Genetics, 2015, 1, e15.	0.9	64
112	Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. Nature Metabolism, 2020, 2, 688-702.	5.1	64
113	Magnetic resonance spectroscopy, Î²-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology, 2011, 77, 951-958.	1.5	63
114	Fractional Anisotropy of the Fornix and Hippocampal Atrophy in AlzheimerÃ¢â‚¬â„¢s Disease. Frontiers in Aging Neuroscience, 2014, 6, 316.	1.7	63
115	Impaired Cognition and Brain Atrophy Decades After Hypertensive Pregnancy Disorders. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, S70-6.	0.9	63
116	Neuroimaging Correlates of Cerebral Microbleeds. Stroke, 2017, 48, 2964-2972.	1.0	63
117	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
118	Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging, 2013, 37, 770-777.	1.9	62
119	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
120	Î²-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62
121	Genome-wide association interaction analysis for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2436-2443.	1.5	61
122	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSPâ€€. Movement Disorders, 2016, 31, 653-662.	2.2	60
123	In vivo ¹⁸ F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
124	Focal hemosiderin deposits and Î²â€amyloid load in the ADNI cohort. Alzheimer's and Dementia, 2013, 9, S116-23.	0.4	59
125	Factors Associated With the Onset and Persistence of Postâ€“Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	4.5	59
126	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59

#	Article	IF	Citations
127	Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimer's and Dementia, 2016, 12, 391-398.	0.4	58
128	White Matter Integrity Determined With Diffusion Tensor Imaging in Older Adults Without Dementia. JAMA Neurology, 2014, 71, 1547.	4.5	57
129	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
130	Brain structure and cognition 3 years after the end of an early menopausal hormone therapy trial. Neurology, 2018, 90, e1404-e1412.	1.5	57
131	The Role of Diffusion Tensor Imaging in Detecting Microstructural Changes in Prodromal <scp>A</scp>lzheimer's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 3-9.	1.9	55
132	Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimerâ€™s disease brains. Molecular Neurodegeneration, 2016, 11, 72.	4.4	55
133	Sex differences in cerebrovascular pathologies on FLAIR in cognitively unimpaired elderly. Neurology, 2018, 90, e466-e473.	1.5	55
134	A blood screening test for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 83-90.	1.2	54
135	Midlife and Lateâ€Life Vascular Risk Factors and White Matter Microstructural Integrity: The Atherosclerosis Risk in Communities Neurocognitive Study. Journal of the American Heart Association, 2017, 6, .	1.6	54
136	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Molecular Neurodegeneration, 2018, 13, 37.	4.4	54
137	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.5	53
138	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
139	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.5	51
140	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.4	51
141	Longitudinal neuroimaging biomarkers differ across Alzheimerâ€™s disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
142	Jump from Pre-mutation to Pathologic Expansion in C9orf72. American Journal of Human Genetics, 2015, 96, 962-970.	2.6	50
143	Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease. JAMA Neurology, 2020, 77, 225.	4.5	50
144	Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism and Related Disorders, 2014, 20, 493-498.	1.1	49

#	Article	IF	Citations
145	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA Neurology, 2016, 73, 1231.	4.5	49
146	Development of a cerebrovascular magnetic resonance imaging biomarker for cognitive aging. Annals of Neurology, 2018, 84, 705-716.	2.8	49
147	Effects of Age on the Glucose Metabolic Changes in Mild Cognitive Impairment. American Journal of Neuroradiology, 2010, 31, 1247-1253.	1.2	48
148	Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families. JAMA Neurology, 2014, 71, 315.	4.5	48
149	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
150	A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression. Alzheimer's and Dementia, 2017, 13, 663-673.	0.4	48
151	<scp>S</scp>tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Movement Disorders, 2017, 32, 115-123.	2.2	48
152	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
153	Effects of hormone therapy on brain structure. Neurology, 2016, 87, 887-896.	1.5	47
154	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
155	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders, 2017, 32, 246-255.	2.2	46
156	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	2.2	46
157	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimerâ€™s disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	3.0	45
158	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45
159	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
160	Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1197-1206.	0.4	45
161	Normal Pressure Hydrocephalus. Neurologic Clinics, 2007, 25, 809-832.	0.8	44
162	Magnetic Resonance Spectroscopy in Common Dementias. Neuroimaging Clinics of North America, 2013, 23, 393-406.	0.5	44

#	Article	IF	Citations
163	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 27-34.	1.2	44
164	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
165	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
166	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimerâ€™s disease. Nature Communications, 2021, 12, 2311.	5.8	44
167	Multipleâ€dose ponezumab for mildâ€toâ€moderate Alzheimer's disease: Safety and efficacy. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 339-347.	1.8	43
168	Acrossâ€vendor standardization of semiâ€LASER for singleâ€voxel MRS at 3T. NMR in Biomedicine, 2021, 34, e4218.	1.6	43
169	Global and local ancestry in Africanâ€Americans: Implications for Alzheimer's disease risk. Alzheimer's and Dementia, 2016, 12, 233-243.	0.4	42
170	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	1.6	42
171	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
172	Evaluation of memory endophenotypes for association with CLU , CR1, and PICALM variants in black and white subjects. , 2014, 10, 205-213.		40
173	Prevalence and Natural History of Superficial Siderosis. Stroke, 2017, 48, 3210-3214.	1.0	40
174	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
175	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurology, 2015, 72, 1313.	4.5	39
176	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
177	Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity. Stroke, 2019, 50, 3037-3044.	1.0	39
178	Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. Magnetic Resonance in Medicine, 2018, 79, 1241-1250.	1.9	38
179	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.4	38
180	Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis. Neurology, 2021, 96, e2546-e2557.	1.5	38

#	Article	IF	Citations
181	Changing the face of neuroimaging research: Comparing a new MRI de-facing technique with popular alternatives. NeuroImage, 2021, 231, 117845.	2.1	38
182	White Matter Reference Region in PET Studies of ¹¹C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-Î² Deposition. Journal of Nuclear Medicine, 2018, 59, 1583-1589.	2.8	37
183	Diffuse Lewy body disease manifesting as corticobasal syndrome. Neurology, 2018, 91, e268-e279.	1.5	37
184	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
185	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
186	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	3.7	36
187	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
188	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.4	35
189	Network-driven plasma proteomics expose molecular changes in the Alzheimerâ€™s brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
190	Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 739-749.	1.4	34
191	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.4	34
192	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	4.9	34
193	A Cost Effective Method of Identifying and Recruiting Persons Over 80 Free of Dementia or Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2006, 20, 101-104.	0.6	32
194	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
195	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
196	AutoVOI: realâ€time automatic prescription of volumeâ€ofâ€interest for single voxel spectroscopy. Magnetic Resonance in Medicine, 2018, 80, 1787-1798.	1.9	32
197	Association of white matter microstructural integrity with cognition and dementia. Neurobiology of Aging, 2019, 83, 63-72.	1.5	32
198	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.4	32

#	Article	IF	Citations
199	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
200	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
201	Cerebral microbleed incidence, relationship to amyloid burden. Neurology, 2020, 94, e190-e199.	1.5	31
202	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	2.1	31
203	Magnetic resonance markers for early diagnosis and progression of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2005, 5, 663-670.	1.4	30
204	Association of Kidney Function Biomarkers with Brain MRI Findings: The BRINK Study. Journal of Alzheimer's Disease, 2016, 55, 1069-1082.	1.2	30
205	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
206	Prevalence and Heterogeneity of Cerebrovascular Disease Imaging Lesions. Mayo Clinic Proceedings, 2020, 95, 1195-1205.	1.4	30
207	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
208	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
209	Decreased Glutamate Levels in Patients with Amnestic Mild Cognitive Impairment: An sLASER Proton MR Spectroscopy and PiBâ€PET Study. Journal of Neuroimaging, 2017, 27, 630-636.	1.0	29
210	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
211	Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multiâ€Ethnic (FLAME) cohort. Alzheimer's and Dementia, 2019, 15, 635-643.	0.4	29
212	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. NeuroImage: Clinical, 2019, 21, 101605.	1.4	29
213	Reproductive history and progressive multiple sclerosis risk in women. Brain Communications, 2020, 2, fcaa185.	1.5	28
214	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimerâ€™s Disease: A Diffusion Tensor Imaging Study. Journal of Alzheimer's Disease, 2015, 49, 633-643.	1.2	27
215	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
216	Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease. Neurology, 2015, 85, 790-798.	1.5	27

#	Article	IF	Citations
217	Joint associations of Î²-amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
218	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.4	27
219	Association of Initial Î²-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
220	Biphasic cortical macroâ€•and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.4	27
221	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
222	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	2.4	27
223	Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimer's and Dementia, 2014, 10, 779-789.	0.4	26
224	A nonsense mutation in PRNP associated with clinical Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2656.e13-2656.e16.	1.5	26
225	ABCA7 loss-of-function variants, expression, and neurologic disease risk. Neurology: Genetics, 2017, 3, e126.	0.9	26
226	¹⁸Fâ€AVâ€•1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
227	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
228	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	4.9	26
229	African American exome sequencing identifies potential risk variants at Alzheimer disease loci. Neurology: Genetics, 2017, 3, e141.	0.9	25
230	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	2.8	25
231	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.5	25
232	Apolipoprotein E regulates lipid metabolism and Î±-synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathologica, 2021, 142, 807-825.	3.9	25
233	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
234	Aortic hemodynamics and white matter hyperintensities in normotensive postmenopausal women. Journal of Neurology, 2017, 264, 938-945.	1.8	24

#	Article	IF	Citations
235	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
236	Normal Pressure Hydrocephalus. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 165-186.	0.4	24
237	Role of Î²-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
238	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	1.1	23
239	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	1.5	23
240	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
241	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
242	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. Parkinsonism and Related Disorders, 2018, 50, 99-103.	1.1	22
243	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
244	Association of Longitudinal Î²-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
245	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. Annals of Neurology, 2021, 89, 520-533.	2.8	21
246	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
247	Cognitive and behavioral features of c9FTD/ALS. Alzheimer's Research and Therapy, 2012, 4, 29.	3.0	20
248	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
249	Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations. Annals of Clinical and Translational Neurology, 2019, 6, 1782-1796.	1.7	20
250	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	3.7	20
251	Microbleeds in Atypical Presentations of Alzheimer's Disease: A Comparison to Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2015, 45, 1109-1117.	1.2	19
252	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19

#	Article	IF	Citations
253	Cerebrospinal fluid dynamics disorders. Neurology, 2019, 93, e2237-e2246.	1.5	19
254	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19
255	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19
256	Clinicopathologic and genetic features of multiple system atrophy with Lewy body disease. Brain Pathology, 2020, 30, 766-778.	2.1	19
257	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
258	¹ H-MRS metabolites and rate of Î²-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
259	Investigation of white matter PiB uptake as a marker of white matter integrity. Annals of Clinical and Translational Neurology, 2019, 6, 678-688.	1.7	18
260	A proteomic signature for dementia with Lewy bodies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 270-276.	1.2	18
261	Confirmation of ¹²³I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635.	2.8	18
262	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	0.8	18
263	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
264	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
265	Imaging markers of cerebrovascular pathologies: Pathophysiology, clinical presentation, and risk factors. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 5-14.	1.2	17
266	Regional T₁ relaxation time constants in Ex vivo human brain: Longitudinal effects of formalin exposure. Magnetic Resonance in Medicine, 2017, 77, 774-778.	1.9	17
267	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
268	Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis. Annals of Neurology, 2020, 87, 556-567.	2.8	17
269	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
270	Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17

#	Article	IF	Citations
271	Pickâ€™s disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17
272	Can aerobic exercise protect against dementia?. Alzheimer's Research and Therapy, 2011, 3, 6.	3.0	16
273	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
274	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
275	Impact of menopausal hormone formulations on pituitary-ovarian regulatory feedback. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2019, 317, R912-R920.	0.9	15
276	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	4.5	15
277	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
278	Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimer's and Dementia, 2014, 10, 62-66.	0.4	14
279	Genetic variants associated with susceptibility to psychosis inÂlate-onset Alzheimerâ€™s disease families. Neurobiology of Aging, 2015, 36, 3116.e9-3116.e16.	1.5	14
280	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
281	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
282	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimerâ€™s Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
283	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	2.4	14
284	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
285	Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration. Frontiers in Neurology, 2020, 11, 80.	1.1	13
286	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.4	13
287	Î²-Amyloid PET and ¹²³ I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
288	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13

#	Article	IF	Citations
289	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
290	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	1.5	12
291	Risk factors of neurovascular ageing in women. Journal of Neuroendocrinology, 2020, 32, e12777.	1.2	12
292	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
293	Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank. Parkinsonism and Related Disorders, 2021, 89, 155-161.	1.1	12
294	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
295	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
296	Plasma Biomarkers of Alzheimerâ€™s Disease in African Americans. Journal of Alzheimer's Disease, 2021, 79, 323-334.	1.2	11
297	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11
298	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
299	Personal, reproductive, and familial characteristics associated with bilateral oophorectomy in premenopausal women: A population-based case-control study. Maturitas, 2018, 117, 64-77.	1.0	10
300	Predictors of adverse outcomes and cost after surgical management for idiopathic normal pressure hydrocephalus: Analyses from a national database. Clinical Neurology and Neurosurgery, 2020, 197, 106178.	0.6	10
301	Prevalence and Trends in Management of Idiopathic Normal Pressure Hydrocephalus in the United States: Insights from the National Inpatient Sample. World Neurosurgery, 2021, 145, e38-e52.	0.7	10
302	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
303	2021 marks a new era for Alzheimer's therapeutics. Lancet Neurology, The, 2022, 21, 3-4.	4.9	10
304	Concurrent variably protease-sensitive prionopathy and amyotrophic lateral sclerosis. Acta Neuropathologica, 2014, 128, 313-315.	3.9	9
305	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
306	Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise?. Sleep, 2019, 42, .	0.6	9

#	Article	IF	Citations
307	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.5	9
308	Menopausal hormone therapy, blood thrombogenicity, and development of white matter hyperintensities in women of the Kronos Early Estrogen Prevention Study. Menopause, 2020, 27, 305-310.	0.8	9
309	Magnetic resonance spectroscopy in the rodent brain: Experts' consensus recommendations. NMR in Biomedicine, 2021, 34, e4325.	1.6	9
310	Cerebral Microbleeds. Stroke, 2021, 52, 2347-2355.	1.0	9
311	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
312	1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults. Neurobiology of Aging, 2022, 112, 16-26.	1.5	9
313	Disproportionately enlarged subarachnoid-space hydrocephalus (DESH) in normal pressure hydrocephalus misinterpreted as atrophy: autopsy and radiological evidence. Neurocase, 2019, 25, 151-155.	0.2	8
314	Associations of pituitary-ovarian hormones and white matter hyperintensities in recently menopausal women using hormone therapy. Menopause, 2020, 27, 872-878.	0.8	8
315	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	2.4	8
316	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
317	African American Dementia Caregiver Problem Inventory: Descriptive analysis and initial psychometric evaluation.. Rehabilitation Psychology, 2017, 62, 25-35.	0.7	8
318	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
319	Development of ¹ H MRS biomarkers for tracking early predementia Alzheimer disease. Neurology, 2019, 92, 209-210.	1.5	7
320	Our Efforts in Understanding Normal Pressure Hydrocephalus: Learning from the 100 Most Cited Articles by Bibliometric Analysis. World Neurosurgery, 2020, 137, 429-434.e13.	0.7	7
321	Long-term ovarian hormone deprivation alters functional connectivity, brain neurochemical profile and white matter integrity in the Tg2576 amyloid mouse model of Alzheimer's disease. Neurobiology of Aging, 2021, 102, 139-150.	1.5	7
322	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	2.1	7
323	Spontaneous amyloid-related imaging abnormalities in a cognitively normal adult. Neurology, 2014, 83, 1771-1772.	1.5	6
324	Chiari 1 Malformation Presenting as Central Sleep Apnea during Pregnancy: A Case Report, Treatment Considerations, and Review of the Literature. Frontiers in Neurology, 2014, 5, 195.	1.1	6

#	Article	IF	Citations
325	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. Brain, 2016, 139, 1005-1007.	3.7	6
326	High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus. Clinical Neurology and Neurosurgery, 2020, 197, 106099.	0.6	6
327	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations. Brain, 2022, 145, 2472-2485.	3.7	6
328	Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clinic Proceedings, 2018, 93, 300-306.	1.4	5
329	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. NeuroImage: Clinical, 2020, 28, 102481.	1.4	5
330	Incorporating Sex as a Biological Variable into Clinical and Translational Research Training. Journal of Women's Health, 2020, 29, 865-867.	1.5	5
331	Study of Symptomatic vs. Silent Brain Infarctions on MRI in Elderly Subjects. Frontiers in Neurology, 2021, 12, 615024.	1.1	5
332	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	3.9	5
333	Plugâ€andâ€play advanced magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 2022, 87, 2613-2620.	1.9	5
334	Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimerâ€™s Disease Genes in African Americans Identifies Novel PSEN Variants. Journal of Alzheimer's Disease, 2017, 56, 1215-1222.	1.2	4
335	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
336	Peripheral Markers of Neurovascular Unit Integrity and Amyloid-Î² in the Brains of Menopausal Women. Journal of Alzheimer's Disease, 2021, 80, 397-405.	1.2	4
337	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. American Journal of Neurodegenerative Disease, 2016, 5, 94-101.	0.1	4
338	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.4	4
339	Clinical Deep Phenotyping of ABCA7 Mutation Carriers. Neurology: Genetics, 2022, 8, e655.	0.9	4
340	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
341	An MRIâ€Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. Journal of Neuroimaging, 2016, 26, 264-268.	1.0	3
342	Case Studies Illustrating Focal Alzheimerâ€™s, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia. Neurologic Clinics, 2016, 34, 699-716.	0.8	3

#	Article	IF	Citations
343	Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. Journal of Psychiatry and Brain Science, 2019, 4, .	0.3	3
344	MR spectroscopy, APOE genotype, and evolving Î²-amyloid pathology. Neurology, 2016, 86, 1750-1751.	1.5	2
345	[O2â€“07â€“06]: CHANGES IN BRAIN STRUCTURE THREE YEARS AFTER THE END OF MENOPAUSAL HORMONE THERAPIES IN A RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P570.	0.4	2
346	Reply to letter: Basis of cingulate island sign may differ in dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 761-762.	2.2	2
347	Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans. EBioMedicine, 2022, , 103929.	2.7	2
348	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.4	2
349	[P3â€“356]: VENTRICULOMEGALY IS A BIOMARKER OF GAIT AND COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1092.	0.4	1
350	[O1â€“02â€“05]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. Alzheimer's and Dementia, 2017, 13, P187.	0.4	1
351	Multimodal imaging in RBD â€" present and future. Nature Reviews Neurology, 2018, 14, 574-576.	4.9	1
352	A Cognitive Neuroscience Perspective on Confabulation: Commentary by Neill Graff-Radford (Jacksonville, FL). Neuropsychoanalysis, 2000, 2, 148-150.	0.1	0
353	IC-01-01: Antemortem PiB binding correlates with postmortem amyloid density in a case with DLB on region of interest analysis. , 2010, 6, S1-S2.		0
354	Early indications of magnetic resonance spectroscopy changes associated with Î²-amyloid load in the cognitively normal. Future Neurology, 2012, 7, 117-118.	0.9	0
355	Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging, 2013, 37, spcone-spcone.	1.9	0
356	Past hormone therapy in older women. Neurology, 2014, 82, 380-381.	1.5	0
357	ARE PLASMA AÎ² MEASURES ASSOCIATED WITH LONGITUDINAL CHANGE IN HIPPOCAMPAL VOLUME?. , 2014, 10, P270-P271.		0
358	F4-02-03: MULTIMODALITY IMAGING FOR EARLY DIAGNOSIS OF DEMENTIA WITH LEWY BODIES. , 2014, 10, P242-P243.		0
359	IC-02-05: Hippocampal volumes predict risk of dementia with lewy bodies in mild cognitive impairment. , 2015, 11, P7-P8.		0
360	O3-01-03: Effects of hormone therapy on brain structure in recently postmenopausal women: A randomized controlled trial. , 2015, 11, P217-P218.		0

#	Article	IF	Citations
361	P1â€337: African American Brain Autopsies from The National Alzheimerâ€™s Coordinating Center. Alzheimer's and Dementia, 2016, 12, P557.	0.4	0
362	O4â€01â€01: Pattern of AVâ€1451 Uptake in Dementia with Lewy Bodies and its Association with Amyloidâ€Beta Deposition. Alzheimer's and Dementia, 2016, 12, P329.	0.4	0
363	Microinfarcts and blood pressure trajectories: response to Dr Niu et al.. Journal of Human Hypertension, 2018, 32, 385-385.	1.0	0
364	F1â€01â€04: DEMENTIA WITH LEWY BODIES. Alzheimer's and Dementia, 2018, 14, P200.	0.4	0
365	Neuroimaging biomarkers in prodromal DLB. Alzheimer's and Dementia, 2020, 16, e042856.	0.4	0
366	Reply to â€œAmyloid Positron Emission Tomography in Multiple Sclerosis: Between Amyloid Deposition and Myelin Damageâ€. Annals of Neurology, 2020, 87, 988-989.	2.8	0
367	Response to â€œLetter to the editor concerning "High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus" by Naylor et al. (Clinical Neurology and Neurosurgery) Tj ETQq1 1 0.784314 rgBT /Overloc 2021, 208, 106820.	0.6	0
368	Regional Brain Stiffness Analysis of Dementia with Lewy Bodies. Journal of Magnetic Resonance Imaging, 2022, 55, 1907-1909.	1.9	0
369	An Extended Analysis of the Histological Variants of Tauâ€Negative FTLD. FASEB Journal, 2008, 22, 58.2.	0.2	0
370	Prior Menopausal Hormone Treatments And Association of Peripheral Markers of Neurovascular Unit Integrity And Î²â€amyloid in The Brains of Menopausal Women. FASEB Journal, 2018, 32, lb449.	0.2	0
371	Quantitative magnetic resonance techniques as surrogate markers of Alzheimerâ€™s disease. Neurotherapeutics, 2004, 1, 196-205.	2.1	0
372	A Neurologist's Practical Approach to Cognitive Impairment. Seminars in Neurology, 2021, 41, 686-698.	0.5	0
373	Dementia with Lewy bodies subtypes identified by cluster analysis on structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.4	0